Data collection took place over November 2016–January 2017 through 14 pharmacies at different regions of Amman. Data were filled by the researchers after informing the pharmacists within pharmacies that the aim of this research was to measure the pregabalin drug misuse/abuse among customers in community pharmacies. To minimize the observers’ effect (i.e. Hawthorne effect), the researchers noticed the interaction between customer and pharmacist standing beside the pharmacist on the dispensing counter, wearing lab coats. A collaboration was made between the researchers and the main pharmacists to detect the abuser customers.
- Phase 2 results for a weekly injection found a mean 24.3% weight loss at 36 weeks with the 60mg dose.
- Pregabalin containing products were placed on the list of restricted drugs use that require a medical prescription to dispense it.
- This list includes drugs with abuse liability, but not competent to be under scheduled controlled drugs (JFDA, 2014).
- Similar finding was observed in a previous study, which aimed to characterize customers dispensed pregabalin at higher than the maximum allowed dose based on data extracted from Swedish national registers (Bodén et al., 2014).
- In 2025, the phentermine-topiramate ER (Qsymia) combination became available in generic form.
- Liraglutide is also approved for type 2 diabetes, under the brand name Victoza.
Product Details
The study was designed as a prospective cross-sectional observational study that was conducted price of pregabalin at different community pharmacies in Amman, the capital of Jordan. Two researchers interviewed all customers of a number of community pharmacies asking for pregabalin products during the observational period (November 2016–January 2017). Compounded versions of medications are made by compounding pharmacies, often to tailor a medication to specific patient needs, like an allergy to an inactive ingredient. For about two years, traditional 503A compounding pharmacies and 503B outsourcing facilities were permitted by the FDA to make compounded semaglutide and tirzepatide under the exceptions for drug shortages.
Clinical monitoring
This list includes drugs with abuse liability, but not competent to be under scheduled controlled drugs (JFDA, 2014). But unfortunately, it is still possible to get such medications easily without fearing of legal accountability. The study underscores the need for regulatory efforts to manage pregabalin abuse, through the addition of pregabalin containing products to the controlled drug list which can’t be purchased without a prescription. Also, pharmacists and customers must be educated at a community pharmacy level regarding potential hazards of pregabalin abuse.